Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia

NCT05929807 is registered in ClinicalTrials.gov with Ascendis Pharma Growth Disorders A/S as lead sponsor.

NCT NCT05929807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05929807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
June 21, 2023
Completion date
March 31, 2039
Enrollment
140 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia